Home
HURA
HURA News

Latest TuHURA Biosciences Inc. Common Stock (HURA) News on May 16, 2025

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

PR Newswire

3 days ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

PR Newswire

11 days ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

MT Newswires

17 days ago

TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

PR Newswire

18 days ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?

Insider Monkey

a month ago

Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?

HURA: 2024 Financial Results

Zacks Small Cap Research

a month ago

HURA: 2024 Financial Results

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

PR Newswire

a month ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

PR Newswire

a month ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a month ago

Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

PR Newswire

a month ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

ACCESS Newswire

2 months ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

ACCESS Newswire

2 months ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

ACCESS Newswire

3 months ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

HURA: Initiating an Immune Response

Zacks Small Cap Research

3 months ago

HURA: Initiating an Immune Response

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

Simply Wall St.

4 months ago

When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)?

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

ACCESSWIRE

5 months ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

ACCESSWIRE

6 months ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

ACCESSWIRE

7 months ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

ACCESSWIRE

7 months ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Share on Social Networks: